Addressing these research directions will help refine the prognostic utility of VEGF‐A, facilitate more personalized risk assessment, and support the development of novel therapeutic strategies aimed at improving outcomes for patients with ALL. The gene discussed is VEGFA; the disease is acute lymphoblastic leukemia.